Skip to main content
. 2020 May 30;4(7):e10367. doi: 10.1002/jbm4.10367

Figure 3.

Figure 3

Pharmacodynamic and pharmacokinetic profiles of M‐PTH/PTHrP and PTH(1–34) in rats. (A) Effects of M‐PTH/PTHrP and PTH(1–34) on blood ionized Ca in TPTX rats by i.v. injection. M‐PTH/PTHrP and PTH(1–34) were injected intravenously in TPTX rats at the indicated doses, and blood samples were collected from the tail vein measured for ionized Ca; data are means ± SE; n = 5 or 3 (PTH(1–34)). *p < 0.05, **p < 0.01, ***p < 0.005 M‐PTH/PTHrP or PTH(1–34) versus TPTX‐vehicle. Blood ionized Ca in TPTX rats injected with M‐PTH/PTHrP at 1.25 and 5.0 nmol/kg at 1 hour were statistically higher than those in vehicle‐injected TPTX rats (*p < 0.05). (B) Pharmacokinetics of M‐PTH/PTHrP and PTH(1–34). M‐PTH/PTHrP and PTH(1–34) each at a dose of 10 nmol/kg were i.v. administered, and blood samples were collected from the jugular vein in the presence of proteinase inhibitors (Aprotinin, Leupeptin, and EDTA) and the plasma samples were assessed for peptide concentration using a hPTHrP(1–34)‐targeted EIA for M‐PTH/PTHrP and an hPTH(1–34)‐targeted ELISA for PTH(1–34). Data are means ± SE; n = 4 (M‐PTH/PTHrP) or 3 (PTH(1–34)).